Ondine Biomedical
Vancouver
About Ondine Biomedical
Ondine Biomedical Inc. (formerly Ondine Biopharma Corporation) is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. The Company is focused on the development and commercialization of its patented light activated technology, Photodisinfection (PDD), for multiple applications. PDD provides antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. Ondine Biomedical Inc. launched is first PDD product Periowave™ in 2006. Periowave™ is used as an adjunctive therapy for the treatment of chronic adult periodontitis (gum disease). In June 2009 Ondine sold its Dental Healthcare Business to PDT Inc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $19.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2024)
- Ticker: lse:OBI
- Website: ondinebio.com
- Phone: (604)669-0555
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ondine-biomedical-56892 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.